Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus

References

• Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013;27(3):495–7. doi: 10.1016/j.hoc.2013.03.001.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–93. doi: 10.1182/blood-2008-07-162503.
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood. 2005;1062:244–51. doi: 10.1182/blood-2004-12-4598.
   Google Scholar
• Cooper N, Kruse A, Kruse C, Watson S, Morgan M, Provan D, Ghanima W, Arnold DM, Tomiyama Y, Santoro C, et al. Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): Impact of ITP on health-related quality of life. Am J Hematol. 2021;96(2):199–207. doi: 10.1002/ajh.26036.
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511–21. doi: 10.1182/blood-2009-01-129155.
   PubMed Web of Science ®Google Scholar
• Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4(11):2377–83. doi: 10.1111/j.1538-7836.2006.02147.x.
   PubMed Web of Science ®Google Scholar
• Kohli R, Chaturvedi S. Epidemiology and clinical manifestations of immune thrombocytopenia. Haemostaseologie. 2019;39(3):238–49. doi: 10.1055/s-0039-1683416.
   PubMed Web of Science ®Google Scholar
• Moulis G, Germain J, Comont T, Brun N, Dingremont C, Castel B, Arista S, Sailler L, Lapeyre-Mestre M, Beyne-Rauzy O, et al. Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. Am J Hematol. 2017 Jun;92(6):493–500. doi: 10.1002/ajh.24702.
   PubMed Web of Science ®Google Scholar
• Efficace F, Mandelli F, Fazi P, Santoro C, Gaidano G, Cottone F, Borchiellini A, Carpenedo M, Simula MP, Di Giacomo V, et al. Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. Am J Hematol. 2016;91(10):995–1001. doi: 10.1002/ajh.24463.
   PubMed Web of Science ®Google Scholar
• Cooper N, Kruse A, Kruse C, Watson S, Morgan M, Provan D, Ghanima W, Arnold DM, Tomiyama Y, Santoro C, et al. Immune thrombocytopenia (ITP) World Impact Survey (iWish): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol. 2021;96(2):188–98. doi: 10.1002/ajh.26045.
   PubMed Web of Science ®Google Scholar
• Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160(11):1630–8. doi: 10.1001/archinte.160.11.1630.
   PubMed Web of Science ®Google Scholar
• Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97(9):2549–54. doi: 10.1182/blood.V97.9.2549.
   PubMed Web of Science ®Google Scholar
• Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, González-López TJ, Grainger J, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–817. doi: 10.1182/bloodadvances.2019000812.
   PubMed Web of Science ®Google Scholar
• Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med. 1989;320(15):974–80. doi: 10.1056/NEJM198904133201505.
   PubMed Web of Science ®Google Scholar
• Kitchens CS. Amelioration of endothelial abnormalities by prednisone in experimental thrombocytopenia in the rabbit. J Clin Invest. 1977;60(5):1129–34. doi: 10.1172/JCI108864.
   PubMed Web of Science ®Google Scholar
• Guidry JA, George JN, Vesely SK, Kennison SM, Terrell DR. Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol. 2009;83(3):175–82. doi: 10.1111/j.1600-0609.2009.01265.x.
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86. doi: 10.1182/blood-2009-06-225565.
   PubMed Web of Science ®Google Scholar
• Matzdorff A, Meyer O, Ostermann H, Kiefel V, Eberl W, Kühne T, Pabinger I, Rummel M. Immune thrombocytopenia - Current diagnostics and therapy: recommendations of a joint working group of DGHO, ÖGHO, SGH, GPOH, and DGTI. Oncol Res Treat. 2018;41(Suppl 5):1–30. doi: 10.1159/000492187.
   PubMed Web of Science ®Google Scholar
• Lozano ML, Sanz MA, Vicente V. Directrices de diagnóstico, tratamiento y seguimiento de la PTI. Recomendaciones del grupo de trabajo de la SEHH y GEPTI. 1ª ed. Madrid: Sociedad Española de Hematología y Hemoterapia; 2020.
   Google Scholar
• Marshall AL, Scarpone R, De Greef M, Bird R, Kuter DJ. Remissions after long-term use of romiplostim for immune thrombocytopenia. Haematologica. 2016;101(12):476–8. doi: 10.3324/haematol.2016.151886.
   PubMed Web of Science ®Google Scholar
• Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527–36. doi: 10.1182/blood-2017-04-748707.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Nagalla S. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. Platelets. 2022;33(2):257–64. doi: 10.1080/09537104.2021.1881952.
   PubMed Web of Science ®Google Scholar
• Chugh S, Darvish-Kazem S, Lim W, Crowther MA, Ghanima W, Wang G, Heddle NM, Kelton JG, Arnold DM. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015;2(2):75–81. doi: 10.1016/S2352-3026(15)00003-4.
   PubMed Web of Science ®Google Scholar
• Bussel J, Arnold DM, Grossbard E, Mayer J, Trelinski J, Homenda W, Hellmann A, Windyga J, Sivcheva L, Khalafallah AA, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921–30. doi: 10.1002/ajh.25125.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Arnold DM, Boxer MA, Cooper N, Mayer J, Zayed H, Tong S, Duliege A-M. Long-term fostamatinib treatment in adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol. 2019;94:546–53. doi: 10.1002/ajh.25444.
   PubMed Web of Science ®Google Scholar
• Boccia R, Cooper N, Ghanima W, Boxer MA, Hill Q, Sholzberg M, Tarantino MD, Todd LK, Tong S, Bussel JB, et al. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. Br J Haematol. 2020;190(6):933–8. doi: 10.1111/bjh.16959.
   PubMed Web of Science ®Google Scholar
• Choi PY, Merriman E, Bennett A, Enjeti AK, Tan CW, Goncalves I, Hsu D, Bird R. Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand. Med J Aust. 2022;216(1):43–52. doi: 10.5694/mja2.51284.
   PubMed Web of Science ®Google Scholar
• Kashiwagi H, Kuwana M, Hato T, Takafuta T, Fujimura K, Kurata Y, Murata M, Tomiyama Y. Committee for the revision of “reference guide for management of adult ITP” blood coagulation abnormalities research team, research on rare and intractable disease supported by health, labour and welfare science research grants. Reference guide for management of adult immune thrombocytopenia in Japan: 2019 revision. Int J Hematol. 2020;111(3):329–51. doi: 10.1007/s12185-019-02790-z.
   PubMed Web of Science ®Google Scholar
• Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances. 2019;3(23):3829–66. doi: 10.1182/bloodadvances.2019000966.
   PubMed Web of Science ®Google Scholar
• Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32(4):1008–15. doi: 10.1046/j.1365-2648.2000.t01-1-01567.x.
   PubMed Web of Science ®Google Scholar
• Terrell DR, Neunert CE, Cooper N, Heitink-Pollé KM, Kruse C, Imbach P, Kühne T, Ghanima W. Immune thrombocytopenia (ITP): Current limitations in patient management. Med (Kaunas). 2020;56(12):667. doi: 10.3390/medicina56120667.
   PubMed Web of Science ®Google Scholar
• Carpenedo M, Baldacci E, Baratè C, Borchiellini A, Buccisano F, Calvaruso G, Chiurazzi F, Fattizzo B, Giuffrida G, Rossi E, et al. Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations. Ther Adv Hematol. 2021;12:20406207211048360. doi: 10.1177/20406207211048361.
   Web of Science ®Google Scholar
• Mahevas M, Michel M, Godeau B. How we manage immune thrombocytopenia in the elderly. Br J Haematol. 2016;173(6):844–56. doi: 10.1111/bjh.14067.
   PubMed Web of Science ®Google Scholar
• Eslick R, McLintock C. Managing ITP and thrombocytopenia in pregnancy. Platelets. 2020;31(3):300–6. doi: 10.1080/09537104.2019.1640870.
   PubMed Web of Science ®Google Scholar
• Liebman HA. Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders. Semin Hematol. 2009;46(1 Suppl 2):S33–6. doi: 10.1053/j.seminhematol.2008.12.004.
   PubMed Web of Science ®Google Scholar
• Bussel JB. Therapeutic approaches to secondary immune thrombocytopenic purpura. Semin Hematol. 2009;46(1 Suppl 2):S44–58. doi: 10.1053/j.seminhematol.2008.12.003.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Yang L, Chen Z, Chen X, Guo Y, Wang X, Dong X, Wang T, Zhang L, Qiu Z, et al. Health-related quality of life measured by the short form 36 in immune thrombocytopenic purpura: a cross-sectional survey in China. Eur J Haematol. 2007;78(6):518–23. doi: 10.1111/j.1600-0609.2007.00844.x.
   PubMed Web of Science ®Google Scholar
• McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008;83:150–4.8. doi: 10.1002/ajh.20992.
   PubMed Web of Science ®Google Scholar
• Leven E, Miller A, Boulad N, Haider A, Bussel JB. Successful discontinuation of eltrombopag treatment in patients with chronic ITP. Blood. 2012;120(21):1085. doi: 10.1182/blood.V120.21.1085.1085.
   Web of Science ®Google Scholar
• Bussel JB, Mahmud SN, Brigstocke SL, Torneten SM. Tapering eltrombopag in patients with chronic ITP: how successful is this and in whom does it work? Blood. 2015;126(23):1054. doi: 10.1182/blood.V126.23.1054.1054.
   Web of Science ®Google Scholar
• Zaja F, Carpenedo M, Baratè C, Borchiellini A, Chiurazzi F, Finazzi G, Lucchesi A, Palandri F, Ricco A, Santoro C, et al. Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: real-world recommendations. Blood Rev. 2020 May;41:100647. doi: 10.1016/j.blre.2019.100647.
   PubMed Web of Science ®Google Scholar
• Cooper N, Hill QA, Grainger J, Westwood JP, Bradbury C, Provan D, Thachil J, Ramscar N, Roy A. Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: results from a modified delphi panel. Acta Haematol. 2021;144(4):418–26. doi: 10.1159/000510676.
   PubMed Web of Science ®Google Scholar